NCT04391764View on ClinicalTrials.gov

Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 6, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Liver Cirrhosis
Interventions
DRUG

Naltrexone

Naltrexone at a dose of 50 mg per day

DRUG

Placebo oral tablet

Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.

Trial Locations (1)

110070

Institute of Liver and Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT04391764 - Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis. | Biotech Hunter | Biotech Hunter